{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T05:15:45Z","timestamp":1794287745038,"version":"4.9.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"7830","license":[{"start":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T00:00:00Z","timestamp":1600819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T00:00:00Z","timestamp":1600819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2020,10,22]]},"DOI":"10.1038\/s41586-020-2798-3","type":"journal-article","created":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T06:03:36Z","timestamp":1600841016000},"page":"516-527","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1994,"title":["SARS-CoV-2 vaccines in development"],"prefix":"10.1038","volume":"586","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4121-776X","authenticated-orcid":false,"given":"Florian","family":"Krammer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,23]]},"reference":[{"key":"2798_CR1","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727\u2013733 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2798_CR2","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270\u2013273 (2020).","journal-title":"Nature"},{"key":"2798_CR3","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41579-018-0118-9","volume":"17","author":"J Cui","year":"2019","unstructured":"Cui, J., Li, F. & Shi, Z. L. Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol. 17, 181\u2013192 (2019).","journal-title":"Nat. Rev. Microbiol."},{"key":"2798_CR4","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1128\/JVI.79.3.1595-1604.2005","volume":"79","author":"L Vijgen","year":"2005","unstructured":"Vijgen, L. et al. Complete genomic sequence of human coronavirus OC43: molecular clock analysis suggests a relatively recent zoonotic coronavirus transmission event. J. Virol. 79, 1595\u20131604 (2005).","journal-title":"J. Virol."},{"key":"2798_CR5","doi-asserted-by":"crossref","first-page":"6338","DOI":"10.1016\/j.vaccine.2008.09.026","volume":"26","author":"JE Martin","year":"2008","unstructured":"Martin, J. E. et al. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a phase I clinical trial. Vaccine 26, 6338\u20136343 (2008).","journal-title":"Vaccine"},{"key":"2798_CR6","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1177\/135965350701200702","volume":"12","author":"JT Lin","year":"2007","unstructured":"Lin, J. T. et al. Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine. Antivir. Ther. 12, 1107\u20131113 (2007).","journal-title":"Antivir. Ther."},{"key":"2798_CR7","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.3389\/fmicb.2019.01781","volume":"10","author":"CY Yong","year":"2019","unstructured":"Yong, C. Y., Ong, H. K., Yeap, S. K., Ho, K. L. & Tan, W. S. Recent advances in the vaccine development against Middle East respiratory syndrome-coronavirus. Front. Microbiol. 10, 1781 (2019).","journal-title":"Front. Microbiol."},{"key":"2798_CR8","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/nrmicro3143","volume":"11","author":"RL Graham","year":"2013","unstructured":"Graham, R. L., Donaldson, E. F. & Baric, R. S. A decade after SARS: strategies for controlling emerging coronaviruses. Nat. Rev. Microbiol. 11, 836\u2013848 (2013).","journal-title":"Nat. Rev. Microbiol."},{"key":"2798_CR9","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/bs.aivir.2019.08.002","volume":"105","author":"MA Tortorici","year":"2019","unstructured":"Tortorici, M. A. & Veesler, D. Structural insights into coronavirus entry. Adv. Virus Res. 105, 93\u2013116 (2019).","journal-title":"Adv. Virus Res."},{"key":"2798_CR10","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260\u20131263 (2020).","journal-title":"Science"},{"key":"2798_CR11","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41564-020-0688-y","volume":"5","author":"M Letko","year":"2020","unstructured":"Letko, M., Marzi, A. & Munster, V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat. Microbiol. 5, 562\u2013569 (2020).","journal-title":"Nat. Microbiol."},{"key":"2798_CR12","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/cr.2008.15","volume":"18","author":"H Wang","year":"2008","unstructured":"Wang, H. et al. SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway. Cell Res. 18, 290\u2013301 (2008).","journal-title":"Cell Res."},{"key":"2798_CR13","doi-asserted-by":"crossref","first-page":"E7348","DOI":"10.1073\/pnas.1707304114","volume":"114","author":"J Pallesen","year":"2017","unstructured":"Pallesen, J. et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc. Natl Acad. Sci. USA 114, E7348\u2013E7357 (2017). This study shows that coronavirus spike proteins can be stabilized by changing two amino acids in S2 to prolines.","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2798_CR14","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.3201\/eid2607.200841","volume":"26","author":"NMA Okba","year":"2020","unstructured":"Okba, N. M. A. et al. Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients. Emerging Infect. Dis. 26, 1478\u20131488 (2020).","journal-title":"Emerging Infect. Dis."},{"key":"2798_CR15","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/s41591-020-0913-5","volume":"26","author":"F Amanat","year":"2020","unstructured":"Amanat, F. et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat. Med. 26, 1033\u20131036 (2020).","journal-title":"Nat. Med."},{"key":"2798_CR16","doi-asserted-by":"crossref","first-page":"915","DOI":"10.4049\/jimmunol.2000583","volume":"205","author":"WB Alsoussi","year":"2020","unstructured":"Alsoussi, W. B. et al. A potently neutralizing antibody protects mice against SARS-CoV-2 infection. J. Immunol. 205, 915\u2013922 (2020).","journal-title":"J. Immunol."},{"key":"2798_CR17","doi-asserted-by":"publisher","unstructured":"Wajnberg, A. et al. SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. Preprint at https:\/\/doi.org\/10.1101\/2020.07.14.20151126 (2020).","DOI":"10.1101\/2020.07.14.20151126"},{"key":"2798_CR18","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-020-2571-7","volume":"584","author":"L Liu","year":"2020","unstructured":"Liu, L. et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584, 450\u2013456 (2020).","journal-title":"Nature"},{"key":"2798_CR19","doi-asserted-by":"publisher","unstructured":"Isho, B. et al. Mucosal versus systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients. Preprint at https:\/\/doi.org\/10.1101\/2020.08.01.20166553 (2020).","DOI":"10.1101\/2020.08.01.20166553"},{"key":"2798_CR20","doi-asserted-by":"publisher","unstructured":"Iyer, A. S. et al. Dynamics and significance of the antibody response to SARS-CoV-2 infection. Preprint at https:\/\/doi.org\/10.1101\/2020.07.18.20155374 (2020).","DOI":"10.1101\/2020.07.18.20155374"},{"key":"2798_CR21","doi-asserted-by":"publisher","unstructured":"Randad, P. R. et al. COVID-19 serology at population scale: SARS-CoV-2-specific antibody responses in saliva. Preprint at https:\/\/doi.org\/10.1101\/2020.05.24.20112300 (2020).","DOI":"10.1101\/2020.05.24.20112300"},{"key":"2798_CR22","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","volume":"181","author":"A Grifoni","year":"2020","unstructured":"Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181, 1489\u20131501.e15 (2020).","journal-title":"Cell"},{"key":"2798_CR23","doi-asserted-by":"publisher","unstructured":"Bao, L. et al. Lack of reinfection in rhesus macaques infected with SARS-CoV-2. Preprint at https:\/\/doi.org\/10.1101\/2020.03.13.990226 (2020).","DOI":"10.1101\/2020.03.13.990226"},{"key":"2798_CR24","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.abc5343","volume":"369","author":"W Deng","year":"2020","unstructured":"Deng, W. et al. Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. Science 369, 818\u2013823 (2020).","journal-title":"Science"},{"key":"2798_CR25","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1126\/science.abc6284","volume":"369","author":"J Yu","year":"2020","unstructured":"Yu, J. et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science 369, 806\u2013811 (2020).","journal-title":"Science"},{"key":"2798_CR26","doi-asserted-by":"publisher","unstructured":"Addetia, A. et al. Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with high attack rate. J. Clin. Microbiol. https:\/\/doi.org\/10.1128\/JCM.02107-20 (2020). This study provides the first evidence that neutralizing antibodies may protect humans from SARS-CoV-2 infection.","DOI":"10.1128\/JCM.02107-20"},{"key":"2798_CR27","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1084\/jem.20020400","volume":"196","author":"GM Spiekermann","year":"2002","unstructured":"Spiekermann, G. M. et al. Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung. J. Exp. Med. 196, 303\u2013310 (2002).","journal-title":"J. Exp. Med."},{"key":"2798_CR28","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0025-6196(12)64949-0","volume":"63","author":"HY Reynolds","year":"1988","unstructured":"Reynolds, H. Y. Immunoglobulin G and its function in the human respiratory tract. Mayo Clin. Proc. 63, 161\u2013174 (1988).","journal-title":"Mayo Clin. Proc."},{"key":"2798_CR29","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1128\/CVI.00475-09","volume":"17","author":"SH Pakkanen","year":"2010","unstructured":"Pakkanen, S. H. et al. Expression of homing receptors on IgA1 and IgA2 plasmablasts in blood reflects differential distribution of IgA1 and IgA2 in various body fluids. Clin. Vaccine Immunol. 17, 393\u2013401 (2010).","journal-title":"Clin. Vaccine Immunol."},{"key":"2798_CR30","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1080\/21645515.2015.1114195","volume":"12","author":"F Su","year":"2016","unstructured":"Su, F., Patel, G. B., Hu, S. & Chen, W. Induction of mucosal immunity through systemic immunization: phantom or reality? Hum. Vaccin. Immunother. 12, 1070\u20131079 (2016).","journal-title":"Hum. Vaccin. Immunother."},{"key":"2798_CR31","unstructured":"Development and Licensure of Vaccines to Prevent COVID-19. https:\/\/www.fda.gov\/media\/139638\/download (FDA, 2020)."},{"key":"2798_CR32","unstructured":"Draft Landscape of COVID-19 Candidate Vaccines. https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines (WHO, accessed 26 September 2020)."},{"key":"2798_CR33","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.cell.2020.06.008","volume":"182","author":"H Wang","year":"2020","unstructured":"Wang, H. et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell 182, 713\u2013721.e9 (2020).","journal-title":"Cell"},{"key":"2798_CR34","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.abc1932","volume":"369","author":"Q Gao","year":"2020","unstructured":"Gao, Q. et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science 369, 77\u201381 (2020).","journal-title":"Science"},{"key":"2798_CR35","doi-asserted-by":"publisher","unstructured":"Zhang, Y.-J. et al. Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy adults aged 18\u201359 years: report of the randomized, double-blind, and placebo-controlled phase 2 clinical trial. Preprint at https:\/\/doi.org\/10.1101\/2020.07.31.20161216 (2020). This was the second study to show immunogenicity of an inactivated SARS-CoV-2 vaccine in humans.","DOI":"10.1101\/2020.07.31.20161216"},{"key":"2798_CR36","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1073\/pnas.070525997","volume":"97","author":"J Talon","year":"2000","unstructured":"Talon, J. et al. Influenza A and B viruses expressing altered NS1 proteins: a vaccine approach. Proc. Natl Acad. Sci. USA 97, 4309\u20134314 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2798_CR37","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.vaccine.2015.11.054","volume":"34","author":"AJ Broadbent","year":"2016","unstructured":"Broadbent, A. J. et al. Evaluation of the attenuation, immunogenicity, and efficacy of a live virus vaccine generated by codon-pair bias de-optimization of the 2009 pandemic H1N1 influenza virus, in ferrets. Vaccine 34, 563\u2013570 (2016).","journal-title":"Vaccine"},{"key":"2798_CR38","doi-asserted-by":"publisher","unstructured":"Chen, W. H. et al. Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminium hydroxide induces protective immunity and reduces immune enhancement. Preprint at https:\/\/doi.org\/10.1101\/2020.05.15.098079 (2020).","DOI":"10.1101\/2020.05.15.098079"},{"key":"2798_CR39","doi-asserted-by":"crossref","first-page":"6159","DOI":"10.3748\/wjg.v11.i39.6159","volume":"11","author":"J Chen","year":"2005","unstructured":"Chen, J. et al. Receptor-binding domain of SARS-CoV spike protein: soluble expression in E. coli, purification and functional characterization. World J. Gastroenterol. 11, 6159\u20136164 (2005).","journal-title":"World J. Gastroenterol."},{"key":"2798_CR40","doi-asserted-by":"publisher","unstructured":"Amanat, F. et al. Introduction of two prolines and removal of the polybasic cleavage site leads to optimal efficacy of a recombinant spike based SARS-CoV-2 vaccine in the mouse model. Preprint at https:\/\/doi.org\/10.1101\/2020.09.16.300970 (2020).","DOI":"10.1101\/2020.09.16.300970"},{"key":"2798_CR41","doi-asserted-by":"publisher","unstructured":"Mercado, N. B. et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature https:\/\/doi.org\/10.1038\/s41586-020-2607-z (2020).","DOI":"10.1038\/s41586-020-2607-z"},{"key":"2798_CR42","doi-asserted-by":"publisher","unstructured":"Keech, C. et al. Phase 1\u20132 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2026920 (2020). This is the first study to report immunogenicity of a recombinant spike vaccine in humans.","DOI":"10.1056\/NEJMoa2026920"},{"key":"2798_CR43","doi-asserted-by":"publisher","unstructured":"Corbett, K. S. et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature https:\/\/doi.org\/10.1038\/s41586-020-2622-0 (2020).","DOI":"10.1038\/s41586-020-2622-0"},{"key":"2798_CR44","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1126\/science.abd0826","volume":"369","author":"CL Hsieh","year":"2020","unstructured":"Hsieh, C. L. et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science 369, 1501\u20131505 (2020).","journal-title":"Science"},{"key":"2798_CR45","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","volume":"395","author":"FC Zhu","year":"2020","unstructured":"Zhu, F. C. et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 395, 1845\u20131854 (2020). This paper reports a first-in-human study with an AdV5-based vaccine candidate against SARS-CoV-2.","journal-title":"Lancet"},{"key":"2798_CR46","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","volume":"396","author":"FC Zhu","year":"2020","unstructured":"Zhu, F. C. et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 396, 479\u2013488 (2020).","journal-title":"Lancet"},{"key":"2798_CR47","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","volume":"396","author":"PM Folegatti","year":"2020","unstructured":"Folegatti, P. M. et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial. Lancet 396, 467\u2013478 (2020). A key study demonstrating immunogenicity of the ChAdOx1 nCoV-19 vaccine in humans.","journal-title":"Lancet"},{"key":"2798_CR48","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-020-00221-3","volume":"5","author":"SP Graham","year":"2020","unstructured":"Graham, S. P. et al. Evaluation of the immunogenicity of prime\u2013boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19. NPJ Vaccines 5, 69 (2020).","journal-title":"NPJ Vaccines"},{"key":"2798_CR49","doi-asserted-by":"publisher","unstructured":"van Doremalen, N. et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature https:\/\/doi.org\/10.1038\/s41586-020-2608-y (2020).","DOI":"10.1038\/s41586-020-2608-y"},{"key":"2798_CR50","doi-asserted-by":"publisher","unstructured":"Logunov, D. Y. et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia. Lancet https:\/\/doi.org\/10.1016\/S0140-6736(20)31866-3 (2020).","DOI":"10.1016\/S0140-6736(20)31866-3"},{"key":"2798_CR51","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.chom.2020.07.018","volume":"28","author":"JB Case","year":"2020","unstructured":"Case, J. B. et al. Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis in mice. Cell Host Microbe 28, 465\u2013474.e4 (2020).","journal-title":"Cell Host Microbe"},{"key":"2798_CR52","doi-asserted-by":"publisher","unstructured":"Sun, W. et al. Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as vaccine candidate. Preprint at https:\/\/doi.org\/10.1101\/2020.07.26.221861 (2020).","DOI":"10.1101\/2020.07.26.221861"},{"key":"2798_CR53","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3390\/vaccines8030472","volume":"8","author":"MA Rohaim","year":"2020","unstructured":"Rohaim, M. A. & Munir, M. A scalable topical vectored vaccine candidate against SARS-CoV-2. Vaccines 8, 472 (2020).","journal-title":"Vaccines"},{"key":"2798_CR54","doi-asserted-by":"publisher","unstructured":"Sun, W. et al. A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine. Preprint at https:\/\/doi.org\/10.1101\/2020.07.30.229120 (2020).","DOI":"10.1101\/2020.07.30.229120"},{"key":"2798_CR55","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","volume":"26","author":"AB Vogel","year":"2018","unstructured":"Vogel, A. B. et al. Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses. Mol. Ther. 26, 446\u2013455 (2018).","journal-title":"Mol. Ther."},{"key":"2798_CR56","doi-asserted-by":"publisher","unstructured":"Laczk\u00f3, D. et al. A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice. Immunity https:\/\/doi.org\/10.1016\/j.immuni.2020.07.019 (2020).","DOI":"10.1016\/j.immuni.2020.07.019"},{"key":"2798_CR57","doi-asserted-by":"publisher","unstructured":"Corbett, K. S. et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2024671 (2020).","DOI":"10.1056\/NEJMoa2024671"},{"key":"2798_CR58","doi-asserted-by":"crossref","unstructured":"Lu, J. et al. A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice. Cell Res. 30, 936\u2013939 (2020).","DOI":"10.1038\/s41422-020-00392-7"},{"key":"2798_CR59","doi-asserted-by":"publisher","unstructured":"Jackson, L. A. et al. An mRNA vaccine against SARS-CoV-2 \u2014 preliminary report. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2022483 (2020). This is the first report on the immunogenicity of Moderna\u2019s mRNA SARS-CoV-2 vaccine candidate in humans.","DOI":"10.1056\/NEJMoa2022483"},{"key":"2798_CR60","doi-asserted-by":"publisher","unstructured":"Mulligan, M. J. et al. Phase 1\/2 study of COVID-19 RNA vaccine BNT162b1 in adults. Nature https:\/\/doi.org\/10.1038\/s41586-020-2639-4 (2020).","DOI":"10.1038\/s41586-020-2639-4"},{"key":"2798_CR61","doi-asserted-by":"publisher","unstructured":"Dinnon, K. H. et al. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures.\u00a0Nature\u00a0https:\/\/doi.org\/10.1038\/s41586-020-2708-8 (2020).","DOI":"10.1038\/s41586-020-2708-8"},{"key":"2798_CR62","doi-asserted-by":"publisher","unstructured":"Gu, H. et al. Adaptation of SARS-CoV-2 in BALB\/c mice for testing vaccine efficacy. Science https:\/\/doi.org\/10.1126\/science.abc4730 (2020).","DOI":"10.1126\/science.abc4730"},{"key":"2798_CR63","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.cell.2020.06.011","volume":"182","author":"AO Hassan","year":"2020","unstructured":"Hassan, A. O. et al. A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies. Cell 182, 744\u2013753.e4 (2020).","journal-title":"Cell"},{"key":"2798_CR64","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.cell.2020.05.027","volume":"182","author":"RD Jiang","year":"2020","unstructured":"Jiang, R. D. et al. Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2. Cell 182, 50\u201358.e8 (2020).","journal-title":"Cell"},{"key":"2798_CR65","doi-asserted-by":"publisher","unstructured":"Rathnasinghe, R. et al. Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection. Preprint at https:\/\/doi.org\/10.1101\/2020.07.06.190066 (2020).","DOI":"10.1101\/2020.07.06.190066"},{"key":"2798_CR66","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.cell.2020.06.010","volume":"182","author":"J Sun","year":"2020","unstructured":"Sun, J. et al. Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment. Cell 182, 734\u2013743.e5 (2020).","journal-title":"Cell"},{"key":"2798_CR67","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41586-020-2312-y","volume":"583","author":"L Bao","year":"2020","unstructured":"Bao, L. et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature 583, 830\u2013833 (2020).","journal-title":"Nature"},{"key":"2798_CR68","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1126\/science.abb7015","volume":"368","author":"J Shi","year":"2020","unstructured":"Shi, J. et al. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2. Science 368, 1016\u20131020 (2020).","journal-title":"Science"},{"key":"2798_CR69","volume":"11","author":"M Richard","year":"2020","unstructured":"Richard, M. et al. SARS-CoV-2 is transmitted via contact and via the air between ferrets. Nat. Commun. 11, 3496 (2020).","journal-title":"Nat. Commun."},{"key":"2798_CR70","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.chom.2020.03.023","volume":"27","author":"YI Kim","year":"2020","unstructured":"Kim, Y. I. et al. Infection and rapid transmission of SARS-CoV-2 in ferrets. Cell Host Microbe 27, 704\u2013709.e2 (2020).","journal-title":"Cell Host Microbe"},{"key":"2798_CR71","doi-asserted-by":"crossref","first-page":"16587","DOI":"10.1073\/pnas.2018975117","volume":"117","author":"M Imai","year":"2020","unstructured":"Imai, M. et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc. Natl Acad. Sci. USA 117, 16587\u201316595 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2798_CR72","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/s41586-020-2342-5","volume":"583","author":"SF Sia","year":"2020","unstructured":"Sia, S. F. et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature 583, 834\u2013838 (2020).","journal-title":"Nature"},{"key":"2798_CR73","first-page":"479","volume":"151","author":"S Mohandas","year":"2020","unstructured":"Mohandas, S. et al. Evaluation of the susceptibility of mice & hamsters to SARS-CoV-2 infection. Indian J. Med. Res. 151, 479\u2013482 (2020).","journal-title":"J. Med. Res."},{"key":"2798_CR74","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1126\/science.abc4776","volume":"369","author":"A Chandrashekar","year":"2020","unstructured":"Chandrashekar, A. et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science 369, 812\u2013817 (2020).","journal-title":"Science"},{"key":"2798_CR75","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41586-020-2324-7","volume":"585","author":"VJ Munster","year":"2020","unstructured":"Munster, V. J. et al. Respiratory disease in rhesus macaques inoculated with SARS-CoV-2. Nature 585, 268\u2013272 (2020).","journal-title":"Nature"},{"key":"2798_CR76","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/s41422-020-0364-z","volume":"30","author":"C Shan","year":"2020","unstructured":"Shan, C. et al. Infection with novel coronavirus (SARS-CoV-2) causes pneumonia in rhesus macaques. Cell Res. 30, 670\u2013677 (2020).","journal-title":"Cell Res."},{"key":"2798_CR77","doi-asserted-by":"crossref","first-page":"503","DOI":"10.24272\/j.issn.2095-8137.2020.202","volume":"41","author":"TZ Song","year":"2020","unstructured":"Song, T. Z. et al. Delayed severe cytokine storm and immune cell infiltration in SARS-CoV-2-infected aged Chinese rhesus macaques. Zool. Res. 41, 503\u2013516 (2020).","journal-title":"Zool. Res."},{"key":"2798_CR78","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-020-2423-5","volume":"585","author":"BN Williamson","year":"2020","unstructured":"Williamson, B. N. et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature 585, 273\u2013276 (2020).","journal-title":"Nature"},{"key":"2798_CR79","doi-asserted-by":"publisher","unstructured":"Guebre-Xabier, M. et al. NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge. Preprint at https:\/\/doi.org\/10.1101\/2020.08.18.256578 (2020).","DOI":"10.1101\/2020.08.18.256578"},{"key":"2798_CR80","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jama.2020.15543","volume":"324","author":"S Xia","year":"2020","unstructured":"Xia, S. et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA 324, 951\u2013960 (2020). This was the first study to show immunogenicity of an inactivated SARS-CoV-2 vaccine in humans.","journal-title":"JAMA"},{"key":"2798_CR81","doi-asserted-by":"publisher","unstructured":"Walsh, E. E. et al. RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study. Preprint at https:\/\/doi.org\/10.1101\/2020.08.17.20176651 (2020). A key study comparing the immunogenicity of Pfizer\u2019s mRNA-based RBD and spike vaccines in humans.","DOI":"10.1101\/2020.08.17.20176651"},{"key":"2798_CR82","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1128\/CVI.00604-15","volume":"23","author":"AJ Dunning","year":"2016","unstructured":"Dunning, A. J. et al. Correlates of protection against influenza in the elderly: results from an influenza vaccine efficacy trial. Clin. Vaccine Immunol. 23, 228\u2013235 (2016).","journal-title":"Clin. Vaccine Immunol."},{"key":"2798_CR83","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1016\/j.vaccine.2009.01.136","volume":"27","author":"JE McElhaney","year":"2009","unstructured":"McElhaney, J. E. et al. Granzyme B: correlates with protection and enhanced CTL response to influenza vaccination in older adults. Vaccine 27, 2418\u20132425 (2009).","journal-title":"Vaccine"},{"key":"2798_CR84","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.vaccine.2012.12.013","volume":"31","author":"CA DiazGranados","year":"2013","unstructured":"DiazGranados, C. A. et al. High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009\u20132010 season. Vaccine 31, 861\u2013866 (2013).","journal-title":"Vaccine"},{"key":"2798_CR85","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1586\/14760584.2014.922416","volume":"13","author":"CJ Luke","year":"2014","unstructured":"Luke, C. J. & Subbarao, K. Improving pandemic H5N1 influenza vaccines by combining different vaccine platforms. Expert Rev. Vaccines 13, 873\u2013883 (2014).","journal-title":"Expert Rev. Vaccines"},{"key":"2798_CR86","unstructured":"The National Academies of Sciences, Engineering and Medicine. Discussion Draft of the Preliminary Framework for Equitable Allocation of COVID-19 Vaccine\u00a0(The National Academies Press, 2020)."},{"key":"2798_CR87","doi-asserted-by":"publisher","unstructured":"Keech, C. et al. First-in-human trial of a SARS CoV 2 recombinant spike protein nanoparticle vaccine. Preprint at https:\/\/doi.org\/10.1101\/2020.08.05.20168435 (2020).","DOI":"10.1101\/2020.08.05.20168435"},{"key":"2798_CR88","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0065-3519(99)80026-3","volume":"41","author":"FW Scott","year":"1999","unstructured":"Scott, F. W. Evaluation of risks and benefits associated with vaccination against coronavirus infections in cats. Adv. Vet. Med. 41, 347\u2013358 (1999).","journal-title":"Adv. Vet. Med."},{"key":"2798_CR89","doi-asserted-by":"crossref","first-page":"e35421","DOI":"10.1371\/journal.pone.0035421","volume":"7","author":"CT Tseng","year":"2012","unstructured":"Tseng, C. T. et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS ONE 7, e35421 (2012).","journal-title":"PLoS ONE"},{"key":"2798_CR90","doi-asserted-by":"crossref","first-page":"e525","DOI":"10.1371\/journal.pmed.0030525","volume":"3","author":"D Deming","year":"2006","unstructured":"Deming, D. et al. Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Med. 3, e525 (2006).","journal-title":"PLoS Med."},{"key":"2798_CR91","doi-asserted-by":"crossref","first-page":"12201","DOI":"10.1128\/JVI.06048-11","volume":"85","author":"M Bolles","year":"2011","unstructured":"Bolles, M. et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 85, 12201\u201312215 (2011).","journal-title":"J. Virol."},{"key":"2798_CR92","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/j.vaccine.2005.01.033","volume":"23","author":"M Czub","year":"2005","unstructured":"Czub, M., Weingartl, H., Czub, S., He, R. & Cao, J. Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets. Vaccine 23, 2273\u20132279 (2005).","journal-title":"Vaccine"},{"key":"2798_CR93","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.bbrc.2014.07.090","volume":"451","author":"SF Wang","year":"2014","unstructured":"Wang, S. F. et al. Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins. Biochem. Biophys. Res. Commun. 451, 208\u2013214 (2014).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2798_CR94","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1021\/acsinfecdis.6b00006","volume":"2","author":"Q Wang","year":"2016","unstructured":"Wang, Q. et al. Immunodominant SARS coronavirus epitopes in humans elicited both enhancing and neutralizing effects on infection in non-human primates. ACS Infect. Dis. 2, 361\u2013376 (2016).","journal-title":"ACS Infect. Dis."},{"key":"2798_CR95","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.vaccine.2006.08.011","volume":"25","author":"YW Kam","year":"2007","unstructured":"Kam, Y. W. et al. Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate Fc\u03b3RII-dependent entry into B cells in vitro. Vaccine 25, 729\u2013740 (2007).","journal-title":"Vaccine"},{"key":"2798_CR96","doi-asserted-by":"crossref","first-page":"e1006565","DOI":"10.1371\/journal.ppat.1006565","volume":"13","author":"KV Houser","year":"2017","unstructured":"Houser, K. V. et al. Enhanced inflammation in New Zealand white rabbits when MERS-CoV reinfection occurs in the absence of neutralizing antibody. PLoS Pathog. 13, e1006565 (2017).","journal-title":"PLoS Pathog."},{"key":"2798_CR97","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1080\/21645515.2016.1177688","volume":"12","author":"AS Agrawal","year":"2016","unstructured":"Agrawal, A. S. et al. Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum. Vaccin. Immunother. 12, 2351\u20132356 (2016).","journal-title":"Hum. Vaccin. Immunother."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-020-2798-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-020-2798-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-020-2798-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T20:32:29Z","timestamp":1668889949000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-020-2798-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,23]]},"references-count":97,"journal-issue":{"issue":"7830","published-print":{"date-parts":[[2020,10,22]]}},"alternative-id":["2798"],"URL":"https:\/\/doi.org\/10.1038\/s41586-020-2798-3","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.738713957.793579975","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.738713957.793580480","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.738713957.793580075","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.738713957.793580252","asserted-by":"object"}]},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,23]]},"assertion":[{"value":"23 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines.\u00a0I would also like to\u00a0note the following, which could be perceived as a conflict of interest: I have previously published work on influenza virus vaccines with S.\u00a0Gilbert (University of Oxford), have consulted for Merck and Pfizer (before 2020), my laboratory is collaborating with Pfizer on animal models of\u00a0SARS-CoV-2, my laboratory is collaborating with N.\u00a0Pardi at the\u00a0University of Pennsylvania on mRNA vaccines against SARS-CoV-2, my laboratory was working in the past\u00a0with GlaxoSmithKline\u00a0on the\u00a0development of influenza virus vaccines\u00a0and one of my mentees has recently joined Moderna.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}